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Type 2 diabetes mellitus (T2DM) is the most
common cause of chronic kidney disease (CKD)
globally. Multiple risk factor management is
essential in such patients to delay the disease
progression [1]; however, the management of
blood glucose presents a particular challenge,
with limited treatment options available
beyond exogenous insulin therapy [2–5].
Patients with T2DM and CKD are at particular
risk of hypoglycemia and its adverse
consequences. Dipeptidyl peptidase-4 (DPP-4)
inhibitors provide a simple, oral, glucose-
sensitive treatment option that does not
increase the risk of hypoglycemia and does not
confound the comorbidities that afflict many of
the other drugs used to treat T2DM [2]. In
addition, DPP-4 inhibitors have been shown to
be associated with no further decline in
estimated glomerular filtration rate (eGFR)
when treating patients with CKD [2]. In recent
years, several DPP-4 inhibitors have become
available and have been extensively evaluated
in patients with T2DM and varying degrees of
renal impairment (RI). These studies have
demonstrated good efficacy and tolerability of
the DPP-4 inhibitor class in these patients, and
have subsequently led to regulatory approval
for the use in patients with T2DM and reduced
eGFR due to CKD. Indeed, only exogenous
insulin and DPP-4 inhibitors are indicated and
now utilized widely across all thresholds of
renal function, including end-stage renal
disease (ESRD; Fig. 1) [2, 6–11].
Unlike linagliptin, with other DPP-4
inhibitors the drug exposure increases with
decreasing renal function (Fig. 1). Thus, doses
or dose frequencies are recommended to be
reduced according to standard renal thresholds
[2, 6–12]. However, changes in renal function
should be seen as a continuum; the thresholds
from mild to moderate RI and from moderate to
severe RI (see Fig. 1 for definitions) are
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convenient delineations based on definitions of
renal function that are in common usage [13],
rather than dictated by clear discontinuities in
exposure. For instance, if a patient is seen at one
visit with an eGFR of about 55 mL/min/1.73 m2
and a few months later at the next visit with an
eGFR at approximately 45 mL/min/1.73 m2, the
physician needs to be aware of this significant
decline in renal function, but its impact on drug
exposure will not be anywhere near the
doubling of exposure implied by the following
dosage strength or frequency
recommendations. The labeling for sitagliptin,
saxagliptin, and alogliptin recommends dosage
strength adjustments depending on the level of
renal function, with presumably no loss of
efficacy [2, 6–8]. Vildagliptin 50 mg efficacy is
maintained when the frequency of dosing is
reduced from twice daily in patients with
normal renal function to once daily in
patients with moderate or severe RI, in
accordance with its label [2, 10]. The dose
adjustments thus require regular monitoring of
renal function, which is also good clinical
practice because in these patients it is
important to closely monitor renal disease
progression. Other than the specifications for
modifications in dose or dose frequency, there
appears to be no difference between each DPP-4
inhibitor with respect to their safety and
tolerability in patients with T2DM and CKD
[11].
In a recent review article on linagliptin [14],
the authors state that ‘‘other widely available
DPP-4 inhibitors are excreted predominantly
via the kidneys and require consideration/
adjustment of dose or are not recommended
in patients with moderate or severe RI or ESRD
requiring dialysis’’. Such statements may cast
doubt over the suitability of DPP-4 inhibitors
other than linagliptin in treating patients with
RI, implying that failure to adequately adjust
the dose of these DPP-4 inhibitors may be
associated with an increased risk of adverse
effects and even nephrotoxicity. The safety and
efficacy of the DPP-4 inhibitor calls as a whole
has been well established in both patients with
normal renal function as well as those with
varying degrees of RI [2, 11]. These data are
derived from patients with stable renal function
at baseline, the question, however, is—what
happens when a patient’s CKD progresses
resulting in an increase in exposure to
unchanged drug or its metabolites consequent
Fig. 1 Renal function threshold and recommended dose of DPP-4 inhibitors in renal impairment patients. b.i.d. twice
daily, DPP-4 dipeptidyl peptidase-4, GFR glomerular ﬁltration rate, o.d. once daily, Rl renal impairment
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upon the declining GFR? In routine clinical
practice, the failure to adjust the dose of DPP-4
inhibitor according to drug’s summary of
product characteristics and eGFR level is likely
a fairly frequent occurrence [15, 16]. A key issue,
therefore, is whether this failure in appropriate
DPP-4 inhibitor dose adjustment in line with
renal function translates into clinically
meaningful consequences? Such concerns are
further compounded by the fact that many
other commonly prescribed drugs are associated
with potential renal toxicity particularly when
there is an increase in pharmacological
exposure due to reduced clearance or
catabolism [17]. However, there is no evidence
for such a link between higher exposure and
renal toxicity with respect to any of the
available DPP-4 inhibitors.
Finally, with regard to the risk of
hypoglycemia with DPP-4 inhibitors, if the
dose is not adjusted according to the label in
patients with moderate/severe RI, it should be
appreciated that DPP-4 inhibitors do not
enhance hypoglycemia risk per se because
elevations in glucagon-like peptide-1 and
glucose insulinotropic polypeptide modulate
insulin and glucagon secretion in a glucose-
sensitive manner [18].
Thus, recommendations to reduce the dose
or dose frequency of DPP-4 inhibitors in
patients with RI are not based on a risk of
adverse effects or renal toxicity, but are aimed
towards achieving drug exposure that yields the
maximum efficacy. Of interest, in a study in
which vildagliptin was dosed at either 50 mg
once or twice daily in patients with ESRD, both
dosing regimens were well tolerated [19], with
no clinically important differences noted
between doses with respect to adverse events.
Thus, any concern that accumulation of
vildagliptin (or its renally excreted
metabolites) results in an increase in renal or
other toxicities is not supported by data. To our
knowledge, this is also true for the entire DPP-4
inhibitor class.
In conclusion, DPP-4 inhibitors represent an
appealing treatment option for the
management of blood glucose control in
people with T2DM and CKD. There is a wealth
of literature, clinical experience, and regulatory
review indicating that there is no evidence of
any safety differences between the various
individual agents within the class. It is
important to remember that there is a
continuum of renal function in patients with
diabetes, with declining renal function
associated with increasing age. As renal kidney
dysfunction progresses, there is an increased
risk of adverse clinical outcomes including
acute kidney injury, falls, frailty, and
mortality. Furthermore, in association with
progressive RI, some coexisting conditions
become more common and increase in
severity, while the risk of adverse events
associated with commonly used drugs such as
metformin increases with declining renal
function, in addition progression to ESRD can
also occur in a small but significant group of
people. The routine monitoring of renal
function thus represents good clinical care of
people with diabetes, beyond an appropriate
dose adjustment of DPP-4 inhibitor. While
there may be differences in the
pharmacological profiles of the individual
DPP-4 inhibitors in relation to renal function,
there is no evidence that these translate into
differences in terms of efficacy, safety, and
nephrotoxic potential.
Current license recommendations for the
marketed DPP-4 inhibitors with respect to
renal function are based on extensive
pharmacological and clinical trial data and
represent the desire to ensure patient exposure
to the minimal doses of drug required to ensure
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clinical efficacy. There is currently, however, no
evidence to suggest that should an inadvertently
inappropriate dosing of any DPP-4 inhibitor take
place in the context of declining renal function
translates into either nephrotoxicity or any
increased risk of adverse events.
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